Going Below the Surface E-newsletter: October 2018
October 24, 2018
As always, we encourage you to share, subscribe and follow us between issues using #GoingBelowTheSurface. Questions or comments to help us improve the newsletter? Drop us a line.
Relying on topline findings — or seizing on conventional wisdom — is one of the great obstacles to going below the surface, and this month’s news highlights those risks. What seemed like good news in the insurance realm, reasonable premium growth, actually hides a looming crisis. Likewise, a year-old cardiology trial held enormous promise for changing practice — and health spending — for the better, but new perspectives on the trial lay bare the challenges of realizing that promise.
A new survey from the Kaiser Family Foundation out this month shows that premiums are rising only modestly for employer-provided health plans: the average single premium is up 3 percent and the average family premium is up 5 percent. While that’s still more than average wage growth last year (2.5 percent), Kaiser characterized the trend as a “period of stability and relatively low cost growth for employer-provided coverage.”
That’s the good news. The bad news is that the premium dollar is buying less. The same survey found that over the past five years, the average deductible has risen 53 percent, meaning that a quarter of those with employer insurance plans face annual deductibles of more than $2,000.
Why It Matters: Moderating premium increases doesn’t come without a cost, and Kaiser suggested that the trend of pushing more and more of the cost burden to consumers may be coming to a head, concluding that “employers may find it increasingly difficult to impose higher cost sharing.” That suggests that other systemic adjustments will have to be considered.
Almost exactly a year ago, the Lancet published the results of the ORBITA trial, which found that — in patients with stable angina — patients who received a stent did no better than patients who received only optimal medical therapy. The results largely overturned conventional wisdom and identified not only an area of medicine rife with unnecessary treatment, but rife with unnecessary and expensive treatment.
Health Affairs ran a series of pieces this month teasing apart the impact of ORBITA, and the prognosis is not encouraging. Cardiologist William Boden suggested, “Likely medical practice will not change in response to ORBITA” because of the firmly held biases of specialists. Shannon Brownlee, the senior vice president of the Lown Institute, argued that ORBITA should prompt a rethinking of how we provide and pay for care, demanding more research before an intervention becomes standard practice and stopping reimbursement for inappropriate care.
Why It Matters: Decades of stent use in stable angina has set cardiology on a course that will be difficult to reverse, and ORBITA is a stark reminder that it is harder to stop doing something than it is to start doing it. Investing — and investing early — in comparative effectiveness research that spans the gamut of interventions will be critical to identifying and stopping wasteful care before it begins.
Accountable care organizations (ACOs) were a hot topic during the past month, with several peer-reviewed journals taking a closer look at whether ACOs, particularly those in the Medicare Shared Savings Program (MSSP), have produced savings for the U.S. health care system. Studies consider the driving factors behind those savings and what policy levers are needed to encourage continued success in these programs.
Since Halloween is almost upon us, we have to ask: Do you have a haunting health care tale or a spooky spending story you’d like to share with us? Pass it along by email or tweet using #GoingBelowTheSurface. For now, we’ll treat you to the following:
About Going Below the Surface
The Going Below the Surface initiative was launched by the National Pharmaceutical Council in 2018 to broaden and improve the conversation around how health care resources are used in the United States. The initiative is aimed at better understanding the roots of the nation’s health spending and investments by promoting a discussion that is firmly based in health policy and systems research. Our goal is to provide clarity on how best to optimize health care spending so that patients receive the right care while simultaneously providing the right incentives to sustain next-generation innovation to improve patient well-being and health system efficiencies. To view the Going Below the Surface partners, visit www.goingbelowthesurface.org.